Evolus, Inc. (NASDAQ: EOLS) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
6.05
+0.21+3.60%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.92 | Insider Own | - | Shs Outstand | 65.85M | Perf Week | -2.34% |
| Market Cap | 384.59M | Forward P/E | 21.90 | EPS next Y | 0.27 | Insider Trans | -0.45% | Shs Float | 50.04M | Perf Month | -13.35% |
| Enterprise Value | 499.70M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 11.80% | Perf Quarter | 8.35% |
| Income | -43.88M | P/S | 1.27 | EPS this Y | 90.79% | Inst Trans | - | Short Ratio | 6.99 | Perf Half Y | 25.32% |
| Sales | 301.79M | P/B | - | EPS next Y | 414.84% | ROA | -19.68% | Short Interest | 5.91M | Perf YTD | -12.18% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | 174.92% | 52W High | 9.69 -37.54% | Perf Year | -34.82% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -18.60% | 52W Low | 4.00 51.30% | Perf 3Y | -25.32% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 25.85% 39.12% | Gross Margin | 65.55% | Volatility | 4.72% 5.14% | Perf 5Y | -46.42% |
| Dividend TTM | - | EV/Sales | 1.66 | EPS Y/Y TTM | -13.58% | Oper. Margin | -9.56% | ATR (14) | 0.32 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.68 | Sales Y/Y TTM | 7.52% | Profit Margin | -14.39% | RSI (14) | 39.63 | Recom | 2.15 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.04 | EPS Q/Q | 44.44% | SMA20 | -5.65% | Beta | 1.36 | Target Price | 15.00 |
| Payout | 0.00% | Debt/Eq | - | Sales Q/Q | 5.80% | SMA50 | -9.56% | Rel Volume | 0.74 | Prev Close | 5.84 |
| Employees | 350 | LT Debt/Eq | -6.61 | Earnings | Aug 05 | SMA200 | -0.72% | Avg Volume | 826.38K | Price | 6.05 |
| IPO Date | Feb 08, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 6.86% 0.85% | Net Debt/EBITDA | -8.20 | Volume | 608,873 | Change | 3.60% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-04-26 | Reiterated | Mizuho Securities | Outperform | $19 → $15 |
| Jan-22-26 | Reiterated | BTIG | Buy | $13 |
| Jan-13-26 | Reiterated | Stifel Nicolaus | $20 → $17 | |
| Aug-06-25 | Downgrade | Needham | Buy → Hold | |
| Oct-03-24 | Reiterated | HC Wainwright & Co. | Buy | |
| Sep-13-24 | Reiterated | Mizuho Securities | Buy | |
| Sep-13-24 | Reiterated | Barclays | Overweight | $16 → $20 |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight | $16 |
| May-13-22 | Upgrade | Barclays | Underweight → Equal Weight | |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
Latest News
Jul-22-26
Jul-10-26
Jul-10-2604:05PM
Jul-08-26
Jul-08-2609:03AM
09:00AM
Jun-17-26
Company
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 286 | 297 | 266 | 202 | 149 | 100 | 57 | 35 | 0 | |
| Cost of Goods Sold Incl. D&A | 98 | 104 | 84 | 62 | 59 | 44 | 18 | 8 | 0 | |
| Gross Profit | 188 | 193 | 182 | 141 | 90 | 56 | 38 | 27 | 0 | |
| Selling, General and Administrative Excl. Other | 217 | 221 | 198 | 165 | 142 | 112 | 98 | 114 | 29 | |
| Research and Development | 8 | 10 | 9 | 15 | 7 | 2 | 2 | 4 | 6 | |
| Other Operating Expense | 3 | -1 | 10 | 10 | 6 | -13 | 91 | 8 | 1 | |
| Operating Income | -38 | -38 | -34 | -49 | -65 | -44 | -153 | -99 | -46 | |
| Interest Expense | 20 | 20 | 19 | 14 | 9 | 1 | 11 | 8 | 1 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 2 | 6 | 3 | 2 | 0 | -1 | 1 | 2 | 0 | |
| Net Income Before Taxes | -58 | -51 | -50 | -62 | -74 | -47 | -163 | -105 | -47 | |
| Income Taxes | 0 | 1 | 1 | 0 | 0 | 0 | 0 | -15 | 0 | |
| Consolidated Net Income | -59 | -52 | -50 | -62 | -74 | -47 | -163 | -90 | -47 | |
| Net Income From Continuing Operations | -59 | -52 | -50 | -62 | -74 | -47 | -163 | -90 | -47 | |
| Net Income | -59 | -52 | -50 | -62 | -74 | -47 | -163 | -90 | -47 | |
| EPS (Recurring) | -0.92 | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | |
| EPS (Basic, Before Extraordinaries) | -0.92 | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | |
| EPS (Diluted) | -0.92 | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | |
| EBITDA | -30 | -23 | -25 | -42 | -54 | -39 | -145 | -92 | -46 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.38 | 1.43 | 2.57 | 2.97 | 2.82 | 3.26 | 2.00 | 9.74 | — | |
| Gross Margin | 65.73 | 64.98 | 68.42 | 69.80 | 60.40 | 56.00 | 66.67 | 77.14 | — | |
| Operating Margin | -13.29 | -12.79 | -12.78 | -24.26 | -43.62 | -44.00 | -268.42 | -282.86 | — | |
| Net Margin | -20.63 | -17.51 | -18.80 | -30.69 | -49.66 | -47.00 | -285.96 | -257.14 | — | |
| Shares Outstanding | 65 | 64 | 62 | 57 | 56 | 50 | 34 | 28 | 24 | |
| Market Capitalization | 393 | 426 | 684 | 600 | 421 | 326 | 114 | 341 | 286 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID | See Remarks | Mar 20 '26 | Sale | 4.75 | 13,669 | 64,929 | 604,700 | Mar 20 |
| Avelar Rui | See Remarks | Mar 20 '26 | Sale | 4.75 | 3,119 | 14,815 | 427,423 | Mar 20 |
| MOATAZEDI DAVID | See Remarks | Mar 17 '26 | Sale | 4.89 | 116,720 | 570,562 | 618,369 | Mar 18 |
| Avelar Rui | See Remarks | Mar 17 '26 | Sale | 4.89 | 29,996 | 146,629 | 430,542 | Mar 18 |
| MOATAZEDI DAVID | See Remarks | Mar 16 '26 | Option Exercise | 0.00 | 67,489 | 0 | 735,089 | Mar 18 |
| Avelar Rui | See Remarks | Mar 16 '26 | Option Exercise | 0.00 | 8,804 | 0 | 460,538 | Mar 18 |
| MOATAZEDI DAVID | See Remarks | Dec 22 '25 | Sale | 7.15 | 10,539 | 75,361 | 354,388 | Dec 29 |
| Avelar Rui | See Remarks | Dec 22 '25 | Sale | 7.15 | 2,261 | 16,168 | 356,821 | Dec 29 |
| Yamagishi-Dressler Tomoko | Chief Marketing Officer | Aug 22 '25 | Sale | 7.51 | 5,722 | 42,972 | 89,949 | Aug 26 |
| Stewart Brady | Director | Aug 15 '25 | Buy | 6.82 | 30,000 | 204,486 | 88,629 | Aug 18 |
| MOATAZEDI DAVID | See Remarks | Jun 16 '25 | Sale | 9.89 | 16,582 | 164,054 | 364,927 | Jun 16 |
| MOATAZEDI DAVID | See Remarks | Jun 13 '25 | Sale | 10.05 | 111,323 | 1,119,141 | 381,509 | Jun 16 |
| White Albert G III | Director | Jun 09 '25 | Buy | 9.45 | 20,000 | 189,000 | 50,378 | Jun 10 |
| Beaver Sandra | Chief Financial Officer | May 13 '25 | Sale | 10.02 | 6,494 | 65,070 | 167,089 | May 14 |
| Avelar Rui | See Remarks | May 12 '25 | Sale | 9.87 | 3,385 | 33,397 | 359,082 | May 14 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.